- Treatment outcomes of BCG vaccine in patients with T1G3 urothelial cancer - a retrospective analysis2012 | Second Faculty of Medicine
- Prognosis of T1G3 bladder cancer patients after the intravesical adjuvant bacillus Calmette-Gue´rin (BCG) immunotherapy.2012 | First Faculty of Medicine
- Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy2018 | First Faculty of Medicine, Second Faculty of Medicine
- Prognostic Factors and Risk Groups in T1G3 Non-Muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Guerin: Results of a Retrospective Multicenter Study of 2451 Patients2015 | First Faculty of Medicine, Second Faculty of Medicine
- The efficacy of BCG TICE and BCG Connaught in a cohort of 2,099 patients with T1G3 non-muscle-invasive bladder cancer2016 | Second Faculty of Medicine
- Risk factors for residual disease at re-TUR in a large cohort of T1G3 patients2021 | First Faculty of Medicine, Second Faculty of Medicine
- Risk factors for residual disease at re-TUR in a large cohort of T1G3 patients2021 | Second Faculty of Medicine, Central Library of Charles University
- Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought2018 | First Faculty of Medicine, Second Faculty of Medicine
- The impact of re-transurethral resection on clinical outcomes in a large multicentre cohort of patients with T1 high-grade/Grade 3 bladder cancer treated with bacille Calmette-Guerin2016 | First Faculty of Medicine, Second Faculty of Medicine
